Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Wegovy (Novo Nordisk) is the FDA‑approved, factory‑made semaglutide product for chronic weight management with known dosing, stability, manufacturing controls and clinical trial evidence.
• “Compounded semaglutide” is made by pharmacies from bulk drug substance or by repackaging and is not FDA‑approved; it may be cheaper but carries greater variability and some safety/regulatory risk.

Details you should know

1. Active ingredient and indication

• Both contain semaglutide as the active molecule (so the pharmacologic effects are similar in principle).
• Wegovy is specifically approved for weight loss at the 2.4 mg weekly regimen and proven in large randomized trials. Compounded semaglutide is usually prescribed off‑label for weight loss and has not gone through the Wegovy clinical trial program.

1. Manufacturing, quality and regulation

• Wegovy is manufactured by Novo Nordisk under strict Good Manufacturing Practices, with batch testing, validated sterility, consistent concentrations, and labeled dosing pens.
• Compounded products come from compounding pharmacies, which are regulated differently (state boards, and some are PCAB‑accredited). They are not “approved” by the FDA the way brand drugs are. That means more variability in potency, purity, sterility and stability from one pharmacy to another, and greater risk of contamination or dosing error.

1. Dosing, formulation and usability

• Wegovy is supplied in prefilled pens with an established titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly) and clear storage/use instructions.
• Compounded semaglutide may come at different concentrations, in vials or syringes or prefilled pens prepared by the pharmacy; this can increase risk of dosing mistakes. Shelf life and storage may differ.

1. Safety, monitoring and known effects

• Wegovy’s safety profile, labeling (thyroid tumor risk in rodents, pancreatitis, gallbladder disease, retinopathy, interactions, pregnancy warnings), and contraindications are well documented.
• Compounded semaglutide carries the same theoretical drug risks because it’s the same molecule, but adverse-event monitoring, reporting and manufacturer support are more limited. Sterility problems (injections) and incorrect dosing are additional risks.

1. Cost, access and legality

• Wegovy is expensive and often not covered for obesity by insurance; Novo Nordisk offers patient support and savings options for eligible patients.
• Compounded options are often less expensive but insurance coverage is variable. The FDA has warned against marketing compounded semaglutide as a substitute for approved products; buying from unregulated online sources is particularly risky.

Practical recommendation

• If you want the product with the most consistent quality, labeled dosing, clinical-trial evidence and manufacturer support: Wegovy (Novo Nordisk). Ask your provider about Novo Nordisk’s patient support/savings programs if cost is a barrier.
• If cost is prohibitive and you’re considering compounded semaglutide, do not buy from marketplaces or unverified sellers. Use a reputable, PCAB‑accredited compounding pharmacy (search the PCAB directory) and ask the pharmacy for: source of the active pharmaceutical ingredient (API), Certificate of Analysis, sterility testing, lot/potency testing, storage instructions, and expiration dating. Also make sure your prescriber is comfortable with monitoring you for side effects.
• Alternative: discuss with your clinician the possibility of using Ozempic (semaglutide for type 2 diabetes) off‑label for weight loss if clinically appropriate — it’s the same molecule but different approved indications/doses and has different insurance coverage patterns.

If you want, tell me whether cost, insurance, or safety is your main concern and I’ll suggest next steps (how to find PCAB‑accredited pharmacies, questions to ask them, or how to enroll in Novo Nordisk support).